FI3733171T3 - Koostumuksia sisältäen hmb:tä ja atp:tä sekä niiden käyttö - Google Patents

Koostumuksia sisältäen hmb:tä ja atp:tä sekä niiden käyttö Download PDF

Info

Publication number
FI3733171T3
FI3733171T3 FIEP20169493.2T FI20169493T FI3733171T3 FI 3733171 T3 FI3733171 T3 FI 3733171T3 FI 20169493 T FI20169493 T FI 20169493T FI 3733171 T3 FI3733171 T3 FI 3733171T3
Authority
FI
Finland
Prior art keywords
hmb
animal
atp
therapeutic method
given
Prior art date
Application number
FIEP20169493.2T
Other languages
English (en)
Finnish (fi)
Inventor
Shawn Baier
Larry Kolb
John Rathmacher
Original Assignee
Metabolic Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Tech Llc filed Critical Metabolic Tech Llc
Application granted granted Critical
Publication of FI3733171T3 publication Critical patent/FI3733171T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FIEP20169493.2T 2012-09-10 2013-09-10 Koostumuksia sisältäen hmb:tä ja atp:tä sekä niiden käyttö FI3733171T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261698919P 2012-09-10 2012-09-10

Publications (1)

Publication Number Publication Date
FI3733171T3 true FI3733171T3 (fi) 2024-01-24

Family

ID=50237697

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20169493.2T FI3733171T3 (fi) 2012-09-10 2013-09-10 Koostumuksia sisältäen hmb:tä ja atp:tä sekä niiden käyttö

Country Status (14)

Country Link
US (1) US10092590B2 (cg-RX-API-DMAC7.html)
EP (2) EP2892522A4 (cg-RX-API-DMAC7.html)
JP (1) JP6258943B2 (cg-RX-API-DMAC7.html)
CN (1) CN105025891B (cg-RX-API-DMAC7.html)
AU (1) AU2013312113B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015005199B1 (cg-RX-API-DMAC7.html)
CA (1) CA2884405C (cg-RX-API-DMAC7.html)
DK (1) DK3733171T3 (cg-RX-API-DMAC7.html)
ES (1) ES2970283T3 (cg-RX-API-DMAC7.html)
FI (1) FI3733171T3 (cg-RX-API-DMAC7.html)
HU (1) HUE065064T2 (cg-RX-API-DMAC7.html)
PL (1) PL3733171T3 (cg-RX-API-DMAC7.html)
PT (1) PT3733171T (cg-RX-API-DMAC7.html)
WO (1) WO2014040067A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018014407A (es) * 2016-05-25 2019-02-21 Tsi Group Ltd Estabilizacion de formulaciones de acido beta-hidroxiisovalerico en capsulas de gel blando.
US10888576B2 (en) * 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028440A (en) 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
CA2142314C (en) 1992-09-16 1999-06-01 Steven L. Nissen Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol
US5348979A (en) 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
JP4010390B2 (ja) * 1999-09-20 2007-11-21 明治乳業株式会社 免疫賦活化組成物
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
US20050027005A1 (en) * 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20060083793A1 (en) * 2004-09-29 2006-04-20 Gardiner Paul T Nutritional composition for promoting muscle performance and acting as hydrogen (H+) blocker
US20060073891A1 (en) * 2004-10-01 2006-04-06 Holt Timothy M Display with multiple user privacy
KR101299885B1 (ko) * 2005-05-27 2013-08-23 코와 가부시키가이샤 피로 회복을 위한 의약
WO2007108071A1 (ja) * 2006-03-17 2007-09-27 Pharma Foods International Co., Ltd. 抗ストレス組成物及びそれを含有する飲食品
PL2381784T3 (pl) * 2008-12-09 2019-01-31 Metabolic Technologies, Inc. Interwencyjny produkt odżywczy w celu poprawy funkcji i siły mięśni
DE102009052640A1 (de) 2009-11-10 2011-05-12 Linde-Lkca-Dresden Gmbh Verfahren und Vorrichtung zur Gaswäsche
WO2011075741A1 (en) * 2009-12-18 2011-06-23 Metabolic Technologies, Inc. Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)

Also Published As

Publication number Publication date
CA2884405A1 (en) 2014-03-13
EP2892522A1 (en) 2015-07-15
ES2970283T3 (es) 2024-05-27
JP2015527408A (ja) 2015-09-17
EP3733171A1 (en) 2020-11-04
EP2892522A4 (en) 2016-01-20
JP6258943B2 (ja) 2018-01-10
EP3733171B1 (en) 2023-10-25
AU2013312113B2 (en) 2018-08-02
BR112015005199A2 (pt) 2017-07-04
CA2884405C (en) 2021-03-30
PL3733171T3 (pl) 2024-03-18
CN105025891B (zh) 2020-01-21
BR112015005199B1 (pt) 2022-09-06
DK3733171T3 (da) 2024-01-29
US10092590B2 (en) 2018-10-09
AU2013312113A1 (en) 2015-03-26
US20140080781A1 (en) 2014-03-20
HUE065064T2 (hu) 2024-05-28
WO2014040067A1 (en) 2014-03-13
HK1217087A1 (zh) 2016-12-23
CN105025891A (zh) 2015-11-04
PT3733171T (pt) 2024-01-31

Similar Documents

Publication Publication Date Title
GEP201706793B (en) Substituted nucleosides, nucleotides and analogs thereof
EA201791999A1 (ru) Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
PH12014501134A1 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
PH12015502588A1 (en) 4`-fluoro-2`-methyl substituted nucleoside derivatives
MX2009008259A (es) Sistemas de ingredientes que comprenden trehalosa, productos alimenticios que contienen trehalosa y metodos para hacerlos.
MX2018003926A (es) Composicion para mejorar el rendimiento.
EA201700336A1 (ru) Композиция, включающая хитин и переваримые белки
EA201591302A1 (ru) Некариесогенное желейное кондитерское изделие
EP3228311A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
EA201492091A1 (ru) Фармацевтические композиции для местного применения, содержащие тербинафид и мочевину
EA201300038A1 (ru) Порошкообразные пищевые жиры
MX2017006639A (es) Metodos y composiciones para preservar la masa corporal magra y promover la perdida de grasa durante la perdida de peso.
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
IN2014MU00327A (cg-RX-API-DMAC7.html)
JP2016512027A5 (cg-RX-API-DMAC7.html)
FI3733171T3 (fi) Koostumuksia sisältäen hmb:tä ja atp:tä sekä niiden käyttö
RU2018103094A (ru) Холодящие составы длительного действия
WO2016189385A3 (en) Enhanced salt compositions and methods of preparation thereof
BR112012013207A2 (pt) método para produzir uma bebida/produto alimentício tendo um aroma e/ou sabor aprimorado, composição para conferir aroma e/ou sabor, produto alimentício, e, métodos para aprimorar um aroma e/ou um sabor de um produto alimentício e para produzir um produto alimentício tendo um aroma e/ou sabor aprimorado.
RU2012132162A (ru) Способ выращивания цыплят-бройлеров
RU2013154564A (ru) Способы и композиции для стимуляции роста безжировой массы тела
EA201390844A1 (ru) Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения
MX2016002714A (es) Composicion y metodo para tropicalizar chocolate.
BR112017028097A2 (pt) ?composição de revestimento de produtos alimentícios, método de preparação da composição e método de revestimento de produtos alimentícios?
MA40567A (fr) Acide palmitoléique destiné à être utilisé pour inhiber la fixation de poux du poisson sur des poissons